This site is intended for U.S. healthcare professionals.
Menu
Close
Efficacy and Safety
Study design
Efficacy results
Safety and Tolerability
Dosing & Infusion Rates
Dosing and rate of administration
Total infusion time
Infusion rate chart
Support & Resources
Materials
Videos
Request a representative
About OCTAGAM 5%
Preparation, storage and handling
Vial sizes and NDC numbers
Biochemical composition and manufacturing
Administration of OCTAGAM 5%1
Drug interactions1
The card body Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam.
** This is an optional area where footnotes can live.
OCTAGAM 5% liquid is contraindicated in patients who have a history of severe systemic hypersensitivity reactions, such as anaphylaxis, to human immunoglobulin and in IgA-deficient patients with antibodies against IgA and history of hypersensitivity.
OCTAGAM 5% liquid is contraindicated in patients with acute hypersensitivity reaction to corn. OCTAGAM 5% liquid contains maltose, a disaccharide sugar, which is derived from corn. Patients known to have corn allergies should avoid using OCTAGAM 5% liquid.
Monitor renal function, including blood urea nitrogen and serum creatinine, and urine output in patients at risk of developing acute renal failure.
Falsely elevated blood glucose readings may occur during and after the infusion of OCTAGAM 5% liquid with testing by some glucometers and test strip systems.
Hyperproteinemia, increased serum osmolarity, and hyponatremia may occur in patients receiving OCTAGAM 5% liquid.
Aseptic meningitis syndrome may occur in patients receiving OCTAGAM 5% liquid, especially with high doses or rapid infusion.
Hemolysis that is either intravascular or due to enhanced red blood cell sequestration can develop subsequent to treatment with OCTAGAM 5% liquid. Risk factors for hemolysis include high doses and non–O–blood group. Closely monitor patients for hemolysis and hemolytic anemia.
Monitor patients for pulmonary adverse reactions (transfusion-related acute lung injury [TRALI]).
OCTAGAM 5% liquid is made from human plasma and may contain infectious agents, eg, viruses and, theoretically, the Creutzfeldt-Jakob disease agent.
The most common adverse reactions reported in >5% of subjects during a clinical trial were headache and nausea. The most serious adverse reactions in treatment with OCTAGAM 5% liquid have been immediate anaphylactic reactions, aseptic meningitis, and hemolytic anemia.
You are encouraged to report adverse events related to Pfizer products by calling 1-800-438-1985 (US only). If you prefer, you may contact the US Food and Drug Administration (FDA) directly. Visit www.fda.gov/MedWatch or call 1-800-FDA-1088.
OCTAGAM® is a registered trademark of Octapharma AG.
Please click here for Full Prescribing Information, including BOXED WARNING.
OCTAGAM® 5% [Immune Globulin Intravenous (Human)] liquid is indicated for the treatment of primary humoral immunodeficiency (PI).
OCTAGAM® 5% [Immune Globulin Intravenous (Human)] liquid is indicated for the treatment of primary humoral immunodeficiency (PI).
Please click here for Full Prescribing Information, including BOXED WARNING.
Please see full Prescribing Information including BOXED WARNING.
OK. We'll need you to sign in before we can determine if you are aligned with a sales representative.
If you select 'Yes', you will be required to enter your username and password in the sign-in form that will appear over this window.
Would you like to sign in now?